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Background: The antitumor lipid edelfosine 
kills yeast by inducing selective 
internalization of raft-associated proteins. 
Results: Impairing vesicular trafficking to the 
vacuole counteracted edelfosine-induced 
plasma membrane alterations without 
affecting internalization of the drug. 
Conclusion: Recycling of raft-associated 
proteins to the plasma membrane prevents 
edelfosine cytotoxicity. 
Significance: Vesicular trafficking is a 
critical process mediating edelfosine 
resistance in yeast that could be extrapolated 
to tumor cells. 
 
 The ether-phospholipid 
edelfosine, a prototype antitumor lipid 
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(ATL), kills yeast cells and selectively kills 
several cancer cell types. To gain insight 
into its mechanism of action, we performed 
chemogenomic screens in the 
Saccharomyces cerevisiae gene-deletion 
strain collection, identifying edelfosine-
resistant mutants. LEM3, AGP2 and DOC1 
genes were required for drug uptake. 
Edelfosine displaced the essential proton 
pump Pma1p from rafts, inducing its 
internalization into the vacuole. Additional 
ATLs, including miltefosine and perifosine 
also displaced Pma1p from rafts to the 
vacuole, suggesting that this process is a 
major hallmark of ATL cytotoxicity in 
yeast. Radioactive and synthetic fluorescent 
edelfosine analogues accumulated in yeast 
plasma membrane rafts and subsequently 
the endoplasmic reticulum. Although both 
edelfosine and Pma1p were initially located 
at membrane rafts, internalization of the 
drug towards endoplasmic reticulum and 
Pma1p to the vacuole followed different 
routes. Drug internalization was not 
dependent on endocytosis and was not 
critical for yeast cytotoxicity. However, 
mutants affecting endocytosis, vesicle 
sorting or trafficking to the vacuole 
including the retromer and ESCRT 
complexes, prevented Pma1p 
internalization and were edelfosine-
resistant. Our data suggest that edelfosine-
induced cytotoxicity involves raft 
reorganization, and retromer- and ESCRT-
mediated vesicular transport and 
degradation of essential raft proteins 
leading to cell death. Cytotoxicity of ATLs 
is mainly dependent on the changes they 
induce in plasma membrane raft-located 
proteins that lead to their internalization 
and subsequent degradation. Edelfosine 
toxicity can be circumvented by 
inactivating genes that then result in the 
recycling of internalized cell-surface 
proteins back to the plasma membrane. 
 
Synthetic ether-linked analogues of 
phosphatidylcholine and 
lysophosphatidylcholine, collectively named 
alkyl-lysophospholipid analogues (ALPs) or 
synthetic antitumor lipids (ATLs) (1,2), 
constitute a family of promising anticancer 
compounds. Unlike most chemotherapeutic 
drugs ATLs do not target DNA but instead act 
at the level of the cell membrane (1-3). Major 
academic and pharmaceutical interest in the 
antitumor mechanisms of ATLs has been 
rekindled by the observation that the 
prototype ATL edelfosine (1-O-octadecyl-2-
O-methyl-rac-glycero-3-phosphocholine; ET-
18-OCH3) (Fig. 1) selectively induces 
apoptosis in cancer cells (4,5), mainly due to 
preferential drug uptake by tumor cells (4-6). 
Edelfosine is the most potent pro-apoptotic 
ATL (7-10). Edelfosine-induced apoptosis in 
hematopoietic cancer cells involves 
accumulation of the drug in lipid rafts 
(4,8,11,12), which results in recruitment and 
clustering of Fas/CD95 death receptor into 
rafts, intracellular activation of the death 
receptor pathway, and apoptosis (4,7,8,12,13). 
Furthermore, edelfosine accumulates in the 
endoplasmic reticulum (ER), promoting an 
ER stress response and apoptosis in solid 
tumor cells (10,14,15). Recent in vivo assays 
highlight the antitumor activity of edelfosine 
in animal models for a number of 
hematological malignancies (8,9) and solid 
tumors (10).  
A major problem in the treatment of 
cancer is the development of drug resistance. 
Understanding the molecular mechanisms 
involved in the generation of resistant 
phenotypes is critical in trying to overcome 
drug resistance and to improve current 
therapy. The antitumor activity of another 
ATL, perifosine (octadecyl (1,1-dimethyl-
piperidino-4-yl)-phosphate, D-21266; Fig. 1), 
is being tested in ongoing clinical trials; and 
miltefosine (Fig. 1) is used in the clinic as a 
palliative treatment for cutaneous metastases 
from breast cancer (16). Gaining insight into 
the mechanisms of action of ATLs, as well as 
in the identification of the molecular 
processes that lead to drug resistant and 
sensitive phenotypes, is of major importance 
for the clinical development of these synthetic 
compounds. 
Edelfosine is cytotoxic against the 
budding yeast Saccharomyces cerevisiae (17), 
although the underlying mechanism is not 
fully understood. The yeast flippase subunit 
Lem3p has been shown to be essential for 
drug uptake (18), and we have previously 
found that edelfosine displaces the essential 
H+-pump Pma1p from plasma membrane 
microdomains, resulting in its degradation 
(17). S. cerevisiae is a useful tool for 
identifying human drug targets and 
modulators of drug activity (19). Comparison 
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of the yeast and human genomes has revealed 
that 30% of known genes involved in human 
disease have yeast orthologs, and a large 
number of yeast genes exhibit a link to human 
disease genes (20,21). In this study, and the 
accompanying paper (Czyz et al.), we 
performed a chemical-genetic screen versus 
the deletion strain set and identified genes that 
led to either increased edelfosine resistance or 
sensitivity. We also synthesized a set of 
fluorescent edelfosine analogues that retained 
the properties of the parent compound and 
allowed its subcellular localization to be 
determined.  
By combining genetic and functional 
approaches, we unveiled a novel mechanism 
of action in the killing of S. cerevisiae that 
may be extrapolative to tumor cells. In 
addition to the identification of three genes 
required for edelfosine uptake our data 
indicate that edelfosine accumulates in lipid 
rafts and ER in S. cerevisiae, and mediates its 
cytotoxic activity by affecting raft protein 
composition which eventually leads to 
intracellular acidification (see accompanying 
paper, Czyz et al.). This alteration in raft 
composition seems to be conserved within the 
ATL family, as it was also observed for 
miltefosine and perifosine. The selective 
displacement of crucial proteins from lipid 
rafts results in their endosome-mediated 
transport to the vacuole, where they undergo 
degradation. The end result is an alteration in 
intracellular pH that eventually leads to cell 
death. The yeast genome-wide screen and 
subsequent experiments performed here 
revealed that vesicular trafficking is a critical 
process mediating edelfosine resistance, with 
mutants that result in increased recycling 
between endosomal compartments and the 
plasma membrane being resistant to 
edelfosine cytoxocity. This is a highly 
conserved process and thus this mode of 
resistance may be extrapolatable from yeast to 
tumor cells.  
 
EXPERIMENTAL PROCEDURES 
 
Yeast strains, plasmids and growth conditions 
The collection of nonessential haploid 
yeast deletion strains derived from parental 
strain BY4741 (MAT a his3Δ1 leu2Δ0 
met15Δ0 ura3Δ0) was obtained from 
Euroscarf. All other strains used in this study 
are listed in Table 1. The endoplasmic 
reticulum marker encoded by ELO3 was 
subcloned into the pUG35 (URA3) vector (22) 
using EcoR1 and Sal1 restriction enzyme 
sites, in frame with green fluorescent protein 
(GFP) coding sequence at its 3’ end. The 
YCplac111-SEC63-GFP (SEC63-GFP under 
control of SEC63 promoter into CEN/LEU2 
vector) was kindly provided by Symeon 
Siniossoglou (University of Cambridge, UK) 
(23). The centromeric plasmid used to express 
Pma1p-GFP (in pRS316, URA3) was kindly 
provided by Annick M. Breton (Institut de 
Biochimie et Génétique Cellulaires, France) 
(24). The centromeric vector YCplac111 
(Stratagene) was used to express the VPS29 
and VPS35 genes in their respective vps29Δ 
and vps35Δ knockout strains. Red fluorescent 
protein (RFP) tagged marker strains (25) for 
the indicated organelles and cellular structures 
(kindly provided by Peter Arvidson, Harvard, 
USA) were used to examine the subcellular 
location of fluorescent edelfosine. 
Yeast strains were grown on standard 
rich medium YPD (1% yeast extract, 2% 
Bacto-peptone, 2% glucose), synthetic 
minimal medium (SD; 0.17% yeast nitrogen 
base without amino acids, 2% glucose and 
supplements according to the requirements of 
the strains), and synthetic complete medium 
(SC; SD medium with 0.079% complete 
supplement mixture (ForMedium, Norwich, 
UK). Agar (2%) was added for solid plates. 
Unless otherwise indicated all yeast cultures 
were incubated at 28°C. 
Growth of cells treated with 
edelfosine was monitored by optical density at 
a wavelength of 595 nm (OD595). A preculture 
was grown overnight in YPD to log-phase. A 
volume of 2 ml of fresh YPD was then 
inoculated to an OD595 of 0.3 and immediately 
treated with edelfosine. Cells were incubated 
for 24 h and sample aliquots were taken at the 
designated times to measure absorbance. 
Edelfosine was routinely used at 15 μM for 
treatment in liquid medium unless otherwise 
indicated. 
 
Large-scale edelfosine resistance screens 
The haploid deletion collection in the 
BY4741 background was screened for 
resistance to edelfosine in SC liquid medium. 
Strains were pinned from 96-well frozen stock 
plates by using a stainless steel 96-pin 
replicator (Nalgene Nunc International) into 
96-well plates containing 150 μl of liquid 
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YPD medium supplemented with G418 (150 
mg/l; Gibco-BRL). The plates were incubated 
at 28°C for 3 days and then pin replicated 
onto liquid SC in 96-well plates containing 
either no drug or 60 μM edefosine. Plates 
were incubated at 28°C and growth was 
quantitatively scored every 24 h over a period 
of 7 days by optical density readings at OD595 
using a microplate spectrophotometer (model 
550; Bio-Rad Laboratories). Edelfosine 
resistance was scored on the basis of the 
relative growth of each mutant against that of 
the wild-type strain in the same plate and with 
that of each mutant strain in plates where no 
drug was added. Putative edelfosine-resistant 
strains identified during the screening of the 
yeast knockout collection were further 
retested at least in duplicate under the same 
conditions described for the screen. Gene 
deletion strains that consistently grew at or 
above a 4-fold higher rate than wild-type cells 
in the presence of 60 μM edelfosine for 72 h 
in five independent screening assays were 
considered drug-resistant. These cutoff 
conditions led to reliable and highly 
reproducible results. Selected resistant strains 
were retested again from the original haploid 
deletion collection stock for drug resistance, 
using 60 μM edelfosine, to minimize those 
arising due to second site mutations 
accumulating in other regions of the genome 
during drug exposure. 
Growth of resistant strains was further 
confirmed in solid medium. Cultures grown in 
96-well plates were resuspended using a 96-
well plate shaker (Microtec; Infors AG), and 
four serial 10-fold dilutions in water were 
done. Five-microliter aliquots of the diluted 
cultures were spotted using a replica plater for 
a 96-well plate (Sigma-Aldrich) to OmniTray 
plates (Nalgene Nunc International) 
containing SC solid medium, to which 
edelfosine was added once the medium had 
cooled to ∼50ºC. The plates were incubated at 
28°C for 3 days and analyzed for cell growth 
every 24 h. 
 
Data analysis and functional group 
classification 
To identify functional clusters of 
genes statistical analysis of overrepresentation 
of functional categories affected by edelfosine 
was performed by using Gene Ontology (GO) 
(26), functional annotations tools from 
FatiGo, FunSpec 
(http://funspec.med.utoronto.ca/) (27), the GO 
term finder at the Saccharomyces Genome 
Database (SGD) 
(http://www.yeastgenome.org/) (28), and the 
MIPS functional catalogue 
(http://mips.gsf.de/genre/proj/yeast). Gene 
classification was done subjectively with 
reliance on the Saccharomyces Genome 
Database (SGD), the Yeast Proteome 
Database, the Comprehensive Yeast Genome 
Database at MIPS and the literature. 
 
Edelfosine uptake in yeast mutants 
[3H]edelfosine uptake was analyzed in 
the 91 yeast mutants that showed the highest 
drug resistance (Supplementary Table S1), as 
described (7) with slight modifications. 
[3H]edelfosine (specific activity, 42 Ci/mmol) 
was synthesized by Amersham Buchler, 
Braunschweig, Germany. Briefly, the mutants 
were incubated at 28oC to late exponential 
phase in 1 ml of YPD in a 96-well microtiter 
plate. The OD595nm of each well was measured 
to ensure the same amount of cells from each 
mutant was present per well. [3H]edelfosine 
(60 µM and 2 x 104 cpm per well) was added 
and the cells were incubated at 28oC at 800 
rpm for 1 h. The non-incorporated 
[3H]edelfosine was washed-out from the 
culture by exhaustive washing (5 times) with 
1 ml of 3% bovine serum albumin (BSA) in 
phosphate buffered saline (PBS). Washed 
cells were resuspended in 500 µl of PBS and 
mixed with 1.5 ml of scintillation liquid. The 
radioactivity incorporated into cells was 
measured in a Beckman liquid scintillation 
counter. The uptake assay was carried out 
three times (data for each mutant strain was 
calculated from three independent biological 
replicates). Deletion mutants with reduced 
edelfosine uptake were complemented with 
the corresponding wild type genes expressed 
from a centromeric plasmid (pRS416), and 
drug uptake was assayed as above. 
 
Detergent-resistant membrane isolation and 
western blots 
Yeast detergent-resistant membranes 
(DRM) were isolated as described (17) from 
total crude membranes. Yeast cells were 
grown to mid-log phase, and an amount of 
cells equivalent to 50 OD595 units was 
untreated or incubated in the presence of 15 
μM edelfosine for the indicated times. Cells 
were then washed three times with PBS and 
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once with 1 M sorbitol containing 10 mM 
NaN3 and 10 mM NaF. The cell pellet was 
stored at -20 °C. Cells were resuspended in 
350 μl of TNE buffer (50 mM Tris-HCl, pH 
7.4, 150 mM NaCl, and 5 mM EDTA, 20 
μg/ml leupeptin, 20 μg/ml aprotinin, 1 mM 
phenylmethylsulfonyl fluoride, and protease 
inhibitor mixture (Roche)), and broken with 
the aid of Fastprep (four 15-s pulses, 5.5 
speed) in the presence of glass beads  at 4°C. 
Unbroken cells were removed by a 500 x g 
spin for 5 min at 4°C, and the resulting 
supernatant (total cell lysate) was centrifuged 
for 3 h at 4°C in an SW40 rotor at 35,000 rpm 
(218,000 x g) to pellet crude cellular 
membranes. The pellet was resuspended in 
Mes-buffered saline (MBS; 25 mM Mes, pH 
6.5, 150 mM NaCl) including 60% sucrose, 
and Triton X-100 was added to a final 
concentration of 1%. After 1 h at 4°C, 
membranes were further disrupted with 
several strokes in a Potter-Elvehjem tissue 
grinder and 350 μl of the extracted 
membranes were mixed with 2.27 ml of 60% 
sucrose in MBS. This was placed at the 
bottom of an ultracentrifuge tube and overlaid 
with a sucrose step gradient from 5 to 50% 
sucrose in MBS (0.89 ml at 5%, 0.89 ml at 
30%, 1.78 ml at 40%, 1.78 ml at 45%, and 
3.54 ml at 50%). Sucrose gradients were 
centrifuged in an SW40 rotor at 38,000 rpm 
(257,000 x g) for 18 h at 4°C in a Beckman 
Optima LE-80K ultracentrifuge and 1-ml 
fractions were collected from the top of the 
gradient. For each fraction, 20 μl was 
subjected to SDS-PAGE, immunoblotting, 
and enhanced chemiluminescence detection. 
For incorporation of edelfosine into 
DRMs, cells were incubated with 15 µM 
[3H]edelfosine (5.3 x 105 dpm/mol) for the 
indicated times and subjected to lipid raft 
isolation as above. 
DRM isolation from yeast treated 
with edelfosine (Inkeysa and Medmark), 
miltefosine (Cayman Chem) and perifosine 
(Aeterna Zentaris) was also performed as 
indicated in the accompanying paper (Czyz et 
al.) using Optiprep gradients. Densitometry 
was performed using Image J (Wayne 
Rasband, National Institutes of Health, USA). 
Experiments were done at least three times. 
For western blot analysis, proteins 
were transferred to polyvinylidene difluoride 
membranes (PVDF) (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK), and blots 
were incubated with antibodies to Pma1p and 
Gas1p (kind gifts of Ramón Serrano, 
Universidad Politécnica de Valencia, Spain, 
and Howard Riezman, University of Geneva, 
Switzerland, respectively), and subsequently 
with horseradish peroxidase-conjugated 
secondary antibodies followed by detection 
using enhanced chemiluminescence. 
  
Edelfosine fluorescent analogues 
Fluorescent analogues of edelfosine 
(Fig. 1A) were synthesized in a way in which 
the physico-chemical properties and 
biological activity of the parent drug remained 
essentially unperturbed. We designed 
synthetic strategies that allowed precise 
control of the changes introduced in the 
structure and properties of the parent drug to 
produce de novo fluorescent bioactive 
analogues of the alkyl-lipid. Synthesis of the 
fluorescent analogues of edelfosine used in 
this study, namely containing the conjugated 
all-(E)-phenyltetraene or all-(E)-
phenyltrienyne blue-emitting chromophores 
(PTE-ET and PTRI-ET, respectively; Figure 
1), and a 2-substituted 
borondifluorodipirromethene group (BODIPY 
or BDP) attached to and aligned with the alkyl 
chain of the ether-lipid (green-emitting Et-
BDP-ET and Yn-BDP-ET; Figure 1) has been 
detailed elsewhere (4,29,30). Spectral features 
of the distinct fluorescent edelfosine 
analogues used in this study have been 
previously described (4,29,30). The filters 
used to examine the PTE-ET and PTRI-ET 
analogues were those for DAPI staining (BP 
546 FT 580 LP 590). The filters to examine 
the BDP-ET analogues were those 
corresponding for GFP (41017 HQ 470/40X 
Q495LP HQ525/50). 
 
Microscopy 
Both Nomarski interference contrast, 
light, and fluorescence microscopy were used 
to visualize different subcellular organelles 
and proteins as well to examine the 
localization and effect on the cell of 
edelfosine. Images were obtained using a Carl 
Zeiss Axioplan 2 microscope. Images were 
acquired using Openlab software 
(PerkinElmer). 
Drug localization was monitored with 
fluorescent analogues of edelfosine that were 
added directly to 1 ml of log-phase cultures in 
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YPD. Cells were incubated in darkness for 30 
min, washed, applied directly to the slide and 
immediately imaged. PTE-ET and PTRI-ET 
were added at a final concentration of 15 µM, 
and due to their proneness to undergo 
photobleaching, pictures were taken as soon 
as the samples were exposed to ultraviolet 
light. Et-BDP-ET and Yn-BDP-ET, which 
have a more intense and resilient 
fluorescence, were added at a final 
concentration of 5 µM and could be imaged 
normally. Images of other fluorescent markers 
were always taken after the analogues were 
imaged. For studies of drug internalization the 
soluble salt Lucifer yellow (LY, Sigma) and 
the lypophilic dye FM 4-64 (Biotium) were 
simultaneously used as endocytosis markers. 
Cells were preincubated for 1 h, at either 4ºC 
or 30ºC, in the presence of 2.5 mg/ml LY and 
10 µM FM 4-64. Cells were washed, 
resuspended in YPD and subsequently 
incubated for 15 min (or 1 h for 0ºC) with 15 
µM PTE-ET, while keeping the previous 
temperature, and imaged immediately 
afterwards. 
Pma1p internalization was monitored 
using strains transformed with a GFP-tagged 
form. Various strains were transformed with 
either a vector carrying the fusion protein or 
an empty one. Cells were grown to early log 
phase (OD595=0.2) and preloaded with 10 μM 
FM4-64 for 45 min. Cells were washed, 
resuspended in the same volume of medium 
and treated with 15 µM edelfosine. After a 4 
hr incubation cells were harvested and 
imaged. 
 
Statistical analysis 
Values are expressed as a mean ± SD 
with the number of experiments indicated. 
 
RESULTS 
 
Cytotoxic activity of edelfosine in S. 
cerevisiae 
In order to set the conditions for 
chemogenomic screens, we first determined 
the minimal concentration necessary to inhibit 
growth of wild-type S. cerevisiae strains in 
liquid culture. Yeast lacking Lem3p (lem3∆), 
which have been reported to be resistant to 
edelfosine (18), were used as a positive 
control of growth inhibition. We also included 
yeast mutants lacking Dnf2p and Drs2p, two 
phospholipid translocases (flippases) involved 
in lipid and endocytic trafficking (31). Lem3p 
is an activator of Dnf2p and other members of 
the phospholipid translocase family. Dnf2p is 
a plasma membrane phospholipid and 
lysophospholipid translocase that can use 
edelfosine as a substrate, while Drs2p is a 
trans-Golgi localized phospholipid translocase 
that affects vesicular trafficking. Edelfosine 
inhibited wild type yeast growth at 15 µM, 
while the lem3Δ strain was resistant to 
edelfosine even at 70 µM (Fig. 2a). The dnf2Δ 
and drs2Δ strains showed an intermediate 
phenotype with growth inhibition at 35 µM 
and 17.5 µM, respectively, probably due to 
partial functional redundancy among them 
and additional members of this protein family 
(32). 
 
Identification of edelfosine-resistant mutants 
in S. cerevisiae 
Next, we performed large-scale 
chemical-genomic screens using a haploid 
collection of S. cerevisiae deletion mutants, 
individually deleted for non-essential genes 
(~4,800 genes) to test for enhanced resistance 
to edelfosine compared to wild-type cells. 
Strains that grew in liquid culture at a rate ≥4-
fold that of wild-type cells in the presence of 
60 μM edelfosine for 72 h in five independent 
screening assays were considered drug-
resistant (Fig. 2b). These cutoff conditions led 
to highly reproducible results. From these 
screens we identified 262 genes whose 
inactivation conferred resistance to edelfosine 
in S. cerevisiae (Table 1, and Supplementary 
Table S1). Functional analysis of these genes 
revealed the enrichment of statistically 
significant clusters of biological processes 
involved in edelfosine resistance. This 
analysis identified genes involved in vesicular 
transport (including ESCRT and retromer 
complexes), protein biosynthesis, and 
mitochondrial processes (Fig. 2c, Table 2, and 
Supplementary Table S1). Table 2 shows 
some of the most relevant genes involved in 
edelfosine resistance regarding vesicular 
traffic and drug uptake. The resistant mutants 
were significantly enriched in endosome- and 
mitochondria- localized proteins. In this work 
we focused on the mechanism of resistance 
conferred by mutants in the endosomal 
trafficking pathways. 
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Mutant strains involved in edelfosine uptake 
Because edelfosine must be 
incorporated by the target cell to exert its 
cytotoxic effect (4,5), we examined whether 
the edelfosine resistance of the selected 
strains was due to deficient drug uptake. 
[3H]edelfosine uptake was analyzed in the 91 
yeast mutants that showed the highest drug 
resistance (Supplementary Table S1) and only 
lem3∆, agp2∆ and doc1∆ mutants resulted in 
drug uptake deficiency (Fig. 2d). This 
phenotype was reverted by transformation of 
each mutant with the corresponding wild-type 
gene (Fig. 2d). It has been previously 
demonstrated that inactivation of LEM3 
blocked edelfosine uptake (18). Interestingly, 
our data indicated that the L-carnitine and 
bleomycin transporter Agp2p (33,34), and 
Doc1p, which is involved in ubiquitination of 
the anaphase promoting complex (APC), were 
also involved in edelfosine uptake (Fig. 2d). 
These results indicate that resistance to 
edelfosine in the majority of mutants 
identified in our screen is not due to reduced 
uptake of the drug. 
 
Fluorescent analogues of edelfosine and drug 
localization to the plasma membrane and ER  
 Because the uptake of edelfosine is 
critical for its cytotoxic action in yeast we 
examined its localization in S. cerevisiae. To 
do so we used a first generation of fluorescent 
edelfosine analogues, tagged with UV-
absorbing all-(E)-phenyltetraene or all-(E)-
phenyltrienyne blue-emitting chromophores 
(PTE-ET and PTRI-ET, respectively) (Fig. 1), 
and a second generation of fluorescent 
analogues where a 2-substituted 
borondifluorodipirromethene group (BODIPY 
or BDP) was attached to and aligned with the 
alkyl chain of the ether-lipid yielding green-
emitting Et-BDP-ET and Yn-BDP-ET 
analogues (Fig. 1) (4,29,30). Absorption and 
emission spectra in the visible wavelength 
range, enhanced fluorescence yield and higher 
resistance to photodegradation of the latter 
analogues improved the lateral resolution of 
living-cell imaging techniques and extended 
the recording time (30).  
The above fluorescent analogues 
preserved the anticancer activity of the parent 
drug, PTE-ET showing the highest killing 
activity (4,15,30). Likewise, similar actions of 
the above fluorescent compounds were found 
in yeast, with PTE-ET being the most 
effective fluorescent analogue in inhibiting 
yeast growth (data not shown). In addition, 
similarly to what was observed with 
radioactive edelfosine (Fig. 2d), no uptake of 
any of the fluorescent edelfosine analogues 
was detected in lem3∆ mutants as compared 
to wild-type yeast (Fig. 3). These data suggest 
that the above fluorescent edelfosine 
analogues behave as bona fide analogues to 
analyze edelfosine localization in yeast. We 
found that all of the emitting edelfosine 
analogues yielded a similar localization 
pattern in yeast (Fig. 3) corresponding to a 
bag-like envelope surrounding the nucleus, 
(visualized by the nuclear marker Sik1p-
RFP), which resembled the morphological 
traits of ER (Fig. 4). On these grounds, PTE-
ET was used hereafter. 
 Using GFP-tagged markers for 
distinct subcellular organelles, we found that 
PTE-ET was mainly localized to the ER, as 
assessed by using Elo3p-GFP as an ER 
marker (Figs. 4, 5 and 6a). We found good co-
localization between PTE-ET and Elo3p-GFP 
(Figs. 4, 5 and 6a), whereas no co-localization 
was observed with markers for other 
subcellular structures and compartments 
including Golgi (Anp1p, Chc1p), spindle pole 
(Spc42p), endosomes (Snf7p), cytoskeleton 
(Sac6p), peroxisomes (Pex3p) and lipid 
droplets (Erg6p) (data not shown). Further 
confirmation of the ER location of edelfosine 
was found by co-localization of PTE-ET 
fluorescent analogue with the ER marker 
Sec63p (Fig. 5). These data suggest that 
fluorescent edelfosine analogues are 
incorporated into the PM and transit to the 
ER. 
 
ER localization of edelfosine is not dependent 
on endocytosis  
 One of the largest clusters of 
edelfosine-resistant mutants comprised strains 
defective in endocytosis. We examined the 
putative involvement of endocytosis in the ER 
localization of edelfosine. Inactivation of 
either END3 or END4 leads to defects in 
endocytosis (35). Our chemogenomic screen 
identified end3∆ as edelfosine resistant in 
addition to endocytosis-related mutants with 
inactivated MYO5, LDB17 or RHO4 genes 
(Table 1). However, PTE-ET was still ER 
localized in the end4 pep4∆ mutant and wild-
type cells (incubated at 4ºC to slow down the 
rate of endocytosis) (Fig. 6b). In both cases, 
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inhibition of endocytosis was confirmed by a 
decrease or block in the uptake of the soluble 
endocytosis marker Lucifer yellow and the 
lipophilic marker FM4-64 (Fig. 6b).  
 These results show that endocytosis 
does not play a role in the ER location of 
edelfosine. Furthermore, because the end4 
pep4∆ mutant is edelfosine-resistant (17), 
drug localization to the ER is not critical for 
its cytotoxicity. 
 
Pma1p internalization, lipid rafts and 
endocytosis in ATL-mediated cytotoxic 
activity 
Because the above data suggested that 
inhibition of endocytosis prevented cell death, 
but was not crucial for edelfosine intracellular 
localization, we hypothesized that an essential 
step for edelfosine toxicity could be the 
internalization of certain membrane proteins 
by endocytosis. We have previously shown 
that edelfosine accumulates in plasma 
membrane lipid rafts in S. cerevisiae 
displacing Pma1p from these membrane 
microdomains resulting in Pma1p transit to 
the vacuole (17). In this regard, we found that 
incubation of yeast at 4ºC abrogated 
internalization of GFP-tagged Pma1p 
following edelfosine treatment, but not the 
intracellular location of edelfosine (Figs. 6b 
and 6c). 
We went on to analyze displacement 
of proteins from lipid rafts by edelfosine. The 
100-kDa yeast lipid raft protein Pma1p was 
mainly located in fractions 4-6 of the sucrose 
gradient of untreated S. cerevisisae, thus 
identifying the raft-enriched fractions (Fig. 7a, 
inset). As shown in Fig. 7a, we found that 
edelfosine was mainly located in non-raft 
fractions at early time points, but became 
enriched in rafts at longer incubation times. 
Interestingly, edelfosine accumulation in rafts 
was accompanied by Pma1p displacement 
from these membrane domains (Figs. 7a and 
7b), which was followed by its internalization 
and degradation in the vacuole (17). However, 
the glycosylphosphatidylinositol (GPI) 
anchored protein Gas1p, another lipid raft 
protein, was not displaced from rafts (Fig. 
7b). This Pma1p displacement from rafts was 
blocked in the end4 pep4∆ mutant (Fig. 7b), 
despite the fact that this mutant accumulated 
large amounts of edelfosine in lipid rafts (Fig. 
7a) and drug internalization was not prevented 
(Fig. 6b). Altogether, these results suggest 
that edelfosine and Pma1p are delivered to the 
interior of the cell through distinct 
mechanisms. Thus, Pma1p internalization is 
mediated by endocytosis, whereas edelfosine 
internalization is endocytosis-independent. In 
addition, it is interesting to note that most of 
the edelfosine was visualized intracellularly in 
the ER after 3 h of incubation, while a 
significant amount of the drug was also found 
in lipid rafts (data not shown), suggesting the 
presence of rafts in the ER. This notion is 
further supported by the high proportion of 
edelfosine in rafts in end4 pep4∆ mutant, 
while being visualized in the ER by 
fluorescence microscopy (cf. Figs. 6b and 7a). 
Presumably, resistance in the end4 pep4∆ 
mutant comes from a downstream effect in the 
mechanism of drug toxicity; that is, uptake of 
the drug and its translocation to the ER 
continues, but Pma1p endocytosis/degradation 
is impaired. 
We also found that, like edelfosine, 
the other clinically relevant ATLs miltefosine 
and perifosine were able to induce Pma1p 
displacement from lipid rafts and subsequent 
internalization into the vacuole in yeast, as 
assessed by detergent-resistant membrane 
isolation (Figs. 8a and 8b) and fluorescence 
microscopy (Fig. 8c). In contrast, treatment of 
yeast with non-ATL compounds including 
cycloheximide, brefeldin A or hygromycin B, 
did not promote Pma1p displacement from 
plasma membrane rafts (data not shown). 
Thus, Pma1p displacement from rafts seems 
to be a general feature of ATL action, and not 
a general process occurring under drug-
induced stress. 
 
Involvement of vesicle-mediated transport in 
edelfosine resistance 
A major cluster of edelfosine-resistant 
mutants included genes that mediated 
vesicular trafficking (Table 2, Supplementary 
Table S1, and Fig. 2c). A significant number 
of these genes are engaged in protein sorting 
at late endosomes, a process that seems to act 
as a major determinant for resistance to 
edelfosine. 
Multiple pathways mediate recycling 
of internalized cell-surface proteins from 
endosomes back to the PM. Sorting of 
proteins at endosomes is a critical step for 
recycling. Sorting of proteins can be carried 
out by different protein complexes including 
sorting nexins, retromer complex and ESCRT 
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complex (36). Mutants in all of these 
pathways were identified in our screen. 
We found that deletion of 4 out of the 
5 components (VPS35, VPS29, VPS26/PEP8 
and VPS17) of the retromer, a highly 
conserved protein complex that mediates 
recycling to the PM as well as retrograde 
transport to the trans-Golgi network (TGN) 
(37), resulted in edelfosine resistance (Table 
2). Drug resistance was also observed in 
mutants for the sorting nexins SNX4 and 
SNX42 (Table 2), which participate in an 
alternate retrograde transport mechanism (38). 
Deletion of the proteases KEX1 or KEX2, 
involved in processing cargo proteins, also 
caused drug resistance (Table 2). RAB7 has a 
role in retromer recruitment to endosomes in 
human cells (39), and deletion of its 
functional homolog in yeast YPT7 caused 
edelfosine resistance (Table 2). Deletion of 
two components (VPS52 and VPS54) of the 
Golgi-Associated Retrograde Protein 
complex (GARP) (40) and the only non-
essential member of the SNARE complex, 
TLG2, or the palmitoyltransferase SWF1 
required for Tlg1p stability involved in 
vesicle fusion to the TGN, also led to 
edelfosine resistance (Table 2).  
We examined whether retrograde 
transport was required for the localization of 
edelfosine to the ER. To this aim we used the 
two most edelfosine-resistant strains with 
deletion in retromer genes, namely vps29∆ 
and vps35∆. The involvement of the retromer 
in edelfosine cytotoxicity was confirmed by 
showing that vps29∆ and vps35∆ mutants 
restored the edelfosine-sensitivity phenotype 
when they were transformed with a 
centromeric plasmid containing their cognate 
VPS29 or VPS35 genes (Fig. 9). Next, we 
found that ER location of edelfosine was not 
affected in the vps29∆ and vps35∆ mutants 
(Fig. 10a). PTE-ET localized to the ER in the 
above deletion mutants, as assessed by using 
the ER-specific marker Elo3p-GFP, indicating 
that drug accumulation in the ER is 
independent of retrograde transport. However, 
Pma1p remained largely at the plasma 
membrane in these retromer mutants 
following exposure to edelfosine, as shown by 
fluorescence microscopy with a Pma1p-GFP 
fusion protein (Fig. 10b). These data further 
support that a critical step in edelfosine 
cytotoxicity is displacement of Pma1p from 
lipid rafts for subsequent degradation by the 
vacuole, and not accumulation of edelfosine 
in the ER. 
In addition, our chemogenomic screen 
identified 11 of the 18 known members of 
ESCRT complexes as genes whose 
inactivation results in edelfosine resistance 
(complex 0: VPS27; complex I: 
VPS23/STP22, VPS37/SRN2; complex III: 
DID4/VPS2, VPS24, VPS20; ESCRT III-
related proteins: DID2 and VPS4; and proteins 
associated with ESCRT function: DOA4, 
UBP2 and BRO1) (Table 2). The ESCRT 
complexes comprise sequential steps in the 
internalization of the early endosome 
membrane to form intraluminal vesicles 
(ILV). As the endosome matures it becomes a 
multivesicular body (MVB). Proteins targeted 
to the endosome membrane can be recycled or 
sorted to the MVB that then deliver the ILVs 
to the vacuole (yeast equivalent of the 
lysosome), where proteins are eventually 
degraded. 
 The edelfosine-resistant gene DOA4 
is an ubiquitin isopeptidase required for 
recycling ubiquitin from late endosomes and 
is essential for the maintenance of the free 
ubiquitin pool. Ubiquitination of proteins is a 
major determinant in their recognition by the 
ESCRT complex and subsequent vacuole-
mediated degradation (41). In fact, genes 
coding for the E3 ubiquitin ligase protein 
adaptors BUL2 and BSD2 were also identified 
in our screen (Supplementary Table S1). In 
agreement with these findings, we show in the 
accompanying paper (Czyz et al.) that 
edelfosine indeed induces ubiquitination and 
internalization of not only Pma1p, but also 
nutrient H+ symporters like the arginine 
transporter Can1p and uracil transporter 
Fur4p. 
 Yeast strains defective in retrograde 
transport still deliver edelfosine to the ER, 
however, a higher proportion of Pma1p is 
found at the PM in retromer mutants. This 
implies that recycling of Pma1p, and possibly 
other lipid raft associated proteins, confers 
edelfosine resistance. 
 
DISCUSSION 
 
ATLs such as edelfosine have shown 
promise for cancer treatment, but it has been 
difficult to further optimize their efficacy as 
the mechanism of action of these drugs 
remains to be fully elucidated. In this study 
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we present the first chemogenomic screen 
undertaken to uncover the underlying genetic 
mechanisms that mediate edelfosine 
resistance in yeast. The most powerful aspect 
of carrying out genetic screens is that the 
approach allows identification of unsuspected 
pathways that modulate cell sensitivity and 
resistance to the drug. We had previously 
determined that edelfosine disrupts lateral 
organization of the plasma membrane as an 
early event in its mode of action in yeast (17). 
In this study and the accompanying paper 
(Czyz et al.), we have found that following 
interaction of edelfosine with lipid rafts, 
resistance and sensitivity to this drug is 
mediated through two major processes, 
namely: i) disturbance of pH homeostasis 
(Czyz et al.); and ii) sorting of specific 
proteins at the endosome via sorting nexins 
and retromer at early and late endosomes, 
respectively and by the ESCRT vesicular 
trafficking pathway. 
Based on the results reported here and 
the accompanying paper (Czyz et al.), we 
propose a working model for edelfosine-
mediated cytotoxicity in yeast that involves 
lipid raft reorganization (Fig. 11, a-d) and loss 
of pH homeostasis (Fig. 11e), leading to cell 
death. Loss of lateral organization in the yeast 
plasma membrane is expected to impact a 
number of proteins that use lipid 
microdomains as scaffolds to modulate their 
activity/function. Despite the fact that several 
proteins would be affected, our results 
consistently point to a main role for the 
essential plasma membrane H+-pump Pma1p 
in mediating the toxic effect of edelfosine, as 
well as of the clinically relevant ATLs 
miltefosine and perifosine. Pma1p is tightly 
associated with plasma membrane lipid rafts 
and this interaction is necessary for its 
ATPase activity (42) (Fig. 11a). Lipid rafts 
are highly compact microdomains enriched in 
ergosterol and sphingolipids and treatment 
with edelfosine disrupts these structures (Fig. 
11a). Edelfosine and cholesterol have 
complementary conical geometries, which 
allow both molecules to bind tightly and form 
bilayers in vitro (43). It has been shown that 
edelfosine alters the organization of lipid rafts 
(44), and this biophysical change leads to 
alterations in the raft protein composition 
(4,12,17). This modification in raft 
organization is likely more extensive when 
sphingolipid (FEN1, SUR4) or ergosterol 
(ERG3) metabolic genes are deleted, these 
mutants being hypersensitive to edelfosine 
[Czyz et al. and (17)]. Once edelfosine alters 
lateral organization of the plasma membrane, 
Pma1p is displaced from rafts (17) followed 
by its internalization via endocytosis to late 
endosomes, and then eventually to the vacuole 
to be degraded (Fig. 11, b-c). 
Through the use of radioactive and 
fluorescent edelfosine analogues we provide 
conclusive evidence that rules out the 
endocytic route for entrance of edelfosine into 
yeast. Our data suggest that edelfosine is 
internalized into the ER (Fig. 11d) through a 
non-endocytic pathway, but this intracellular 
location of the drug is not per se crucial for 
edelfosine toxicity in yeast. We interpret the 
retrieval from our edelfosine-resistance screen 
of mutants lacking components in several 
endocytic and trafficking pathways as a way 
to recycle Pma1p back to the plasma 
membrane. The model depicted in Fig. 11 
implies that edelfosine treatment displaces 
Pma1p to the late endosome, and then 
eventually to the vacuole to be degraded. Our 
data suggest a putative mechanism of Pma1p 
degradation involving its ubiquitination (Fig. 
11, c(1) and c(2)), followed by recognition 
through the ESCRT complex (Fig. 11c(3)), a 
process highly conserved in eukaryotes, and 
then incorporation into MVB (Fig. 11c(4)), and 
subsequent degradation in the vacuole (Fig. 
11c(5)). In endosome traffic-defective mutants, 
where the above mechanisms are not wholly 
functional, Pma1p could escape the 
endosome, preventing its entering the 
degradation pathway, and cycle back to the 
plasma membrane (Fig. 11, c(6) and c(7)). 
 In support of this model, it has been 
described that a temperature-sensitive 
conditional mutant of PMA1 (pma1-7, 
Pma1pts) undergoes growth arrest because 
newly synthesized protein is directed to the 
vacuole via endocytic intermediates at the 
restrictive temperature (45). Rerouting of this 
Pma1pts mutant to the plasma membrane and 
a concomitant growth recovery could be 
achieved by inactivation of certain suppressor 
of pma1 (SOP) genes (44). Eight of these SOP 
mutants have defects in endosome-vacuole 
targeting of proteins. Interestingly, half of 
them [vps29Δ, vps35Δ (retromer), vps27Δ 
(ESCRT), vps8Δ (CORVET)] were also 
identified in our resistance screen to 
edelfosine. In vps27Δ and vps8Δ, traffic of an 
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inducible Pma1pts fused to GFP was 
monitored. It was demonstrated that these 
mutations blocked progress of the protein to 
the vacuole allowing its transport from the 
endosome to the plasma membrane (45). In 
this work we show similar results for vps35∆ 
and vps29∆ after treatment with edelfosine 
(Fig. 11, c(6) and c(7)). Thus, the effect of 
edelfosine resembles that of the pma1-7 
mutant, with the difference in the case of 
edelfosine being that Pma1p reaches the 
endocytic compartment from the plasma 
membrane. A blockage in the trafficking 
pathway leading to the vacuole results in 
rerouting of Pma1p back to the plasma 
membrane overcoming the cytotoxic effect. 
 While it has been well documented 
recycling of proteins is enhanced in cells 
lacking ESCRT components, it is intriguing 
how lack of endosomal sorting function 
results in recycling of internalized Pma1p. We 
propose internalized Pma1p destined for 
degradation in the vacuole is scrutinized by 
the sorting machinery, ensuring it does not go 
back to the plasma membrane. Lack of sorting 
allows for diversion of internalized Pma1p to 
return to the plasma membrane. In this regard 
it is interesting to note that lack of the recently 
characterized sorting protein Ere1p (but not 
Ere2p), which is critical for recycling of the 
raft associated transporter Can1p (36), confers 
resistance to edelfosine (Supplementary Table 
S1). Targeting of membranes by the 
prototypic ATL edelfosine is unveiling a 
fascinating network of communication 
between plasma membrane and intracellular 
membranes, that rely on intracellular pH, to 
control cellular growth or death decisions. 
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FIGURE LEGENDS 
 
Figure 1. Chemical structures of ATLs and edelfosine fluorescent analogues. Chemical 
structures of edelfosine (EDLF or ET), the related natural compound lysophosphatidylcholine 
(LysoPC), fluorescent edelfosine analogues PTE-ET, PTRI-ET, Et-BDP-ET and Yn-BDP-ET, and 
the ATLs miltefosine (MLTF), and perifosine (PRIF). 
 
Figure 2. Edelfosine-resistant S. cerevisiae screen and mutants affecting drug uptake. (a) 
Toxicity threshold of two wild-type S. cerevisiae strains (haploid BY4741, diploid BY4743) and 
three single deletion mutants known to exert resistance to edelfosine following 48 h incubation. (b) 
Growth of the complete set of haploid S. cerevisiae yeast deletion mutants in the presence of 60 μM 
edelfosine (EDLF). Each dot (red, deletion mutant; blue, wild-type) represents the growth of each 
yeast strain in the presence of 60 μM edelfosine for 72 h. The dashed line delineates strains 
considered resistant to edelfosine. (c) Functional distribution of the 262 genes found to cause 
resistance to edelfosine when deleted. (d) Uptake of [3H]edelfosine for three resistant strains found 
to have decreased drug incorporation relative to the wild-type (WT, black solid bar). Each pair of 
bars represents a single-gene deletion mutant (black patterned bar) alongside that mutant 
complemented by a centromeric plasmid carrying said gene (white patterned bar). Data shown are 
representative or mean values ± SD of at least three independent experiments. 
 
Figure 3. Uptake of fluorescent analogues of edelfosine depends on LEM3. (a) Wild-type S. 
cerevisiae cells were incubated with the indicated fluorescent edelfosine compounds and imaged. (b) 
lem3Δ cells were incubated and imaged as above. Since little to no intracellular fluorescence was 
observed in lem3Δ cells, higher exposition times had to be used, which accounts for the increased 
noise. Images shown are from representative experiments repeated at least three times. 
 
Figure 4. Localization pattern of different fluorescent analogues of edelfosine in the 
endoplasmic reticulum of S. cerevisiae. (a) PTE-ET localizes in the endoplasmic reticulum as 
shown by the organelle marker Elo3p tagged with GFP. (b) The same distribution pattern can be 
observed with PTRI-ET. (c,d) Et-BDP-ET and Yn-BDP-ET also localize in the endoplasmic 
reticulum as assessed by their visualization around the nucleolus marker Sik1p tagged with RFP and 
close to the vacuole, as seen by differential interference contrast (DIC). 
  
Figure 5.  Quantification of S. cerevisiae cells showing co-localization of PTE-ET with the ER 
markers Elo3p and Sec63p.  (a) Cells carrying a Sec63-GFP (green fluorescence) bearing plasmid, 
as a marker for ER, were incubated with PTE-ET (pseudo-colored red) and imaged. Areas of co-
localization between ER and PTE-ET in the merge panels are yellow. The corresponding light 
microscopy images are also shown. (b) Fluorescence microscopy images of PTE-ET and the ER 
markers Elo3p-GFP and Sec63p-GFP were examined, and stained cells were quantitated for the 
subcellular localization of the edelfosine fluorescent analogue. For each experiment, 150-300 stained 
cells were analyzed. Data shown are representative of mean values ± SD of at least three 
independent experiments. 
 
Figure 6. Edelfosine and Pma1p subcellular localization following drug treatment. (a) 
Edelfosine fluorescent analogue PTE-ET colocalizes with the tagged ER marker protein Elo3p-GFP. 
(b) Influence of decreased endocytosis on drug uptake was assayed by comparing end4 pep4Δ cells 
(kept at the semi-permissive temperature of 25ºC) and wild-type cells switched to 4ºC with wild-type 
cells at 30ºC. Cells were incubated in the presence of the endocytic markers lucifer yellow (LY) and 
FM4-64, and afterwards with PTE-ET. (c) GFP-tagged Pma1p is internalized to the vacuole after 
edelfosine treatment (EDLF) at 30ºC; whereas at a temperature blocking endocytosis (4ºC), this 
process, unlike drug uptake (see panel b), is impaired. Images shown are from representative 
experiments repeated three times. 
 
Figure 7. Edelfosine and Pma1p localization to lipid rafts following drug treatment of S. 
cerevisiae. Aliquots of sucrose gradient fractions for the isolation of lipid rafts from membrane-
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enriched samples were analyzed for [3H]edelfosine (a) and Pma1p (b) distribution. Adjoining figures 
represent fractions of the same samples. (a) [3H]edelfosine distribution in fractions of wild-type cells 
after drug treatment for 15 min (WT 15 min) and 360 min (WT 360 min). Underlined fractions 
correspond to lipid rafts. Drug accumulation in lipid raft fractions is even more remarkable in drug-
resistant end 4pep4Δ cells (end4 pep4Δ 360 min). Inset, Western blot of the raft protein Pma1p in 
untreated wild-type yeast (WT 0 min), identifying fractions 4-6 as raft-enriched fractions. The 
position of Pma1p is indicated by an arrow. (b) Pma1p (arrow) and Gas1p (arrowhead) distribution 
in sucrose gradient fractions obtained from the isolation of lipid rafts. Edelfosine alters Pma1p 
distribution relative to 15-min controls, decreasing its presence in lipid raft fractions. The resistant 
end4 pep4Δ strain manages to keep Pma1p in the edelfosine-enriched lipid rafts. Data shown are 
representative of three experiments performed. 
 
Figure 8. Effect of ATLs on Pma1p localization following ATL treatment in S. cerevisiae. (a) 
Association of Pma1p with detergent-resistant membranes from wild-type yeast cells untreated 
(Control) or treated with 15 μM edelfosine (EDLF), 2.5 μM miltefosine (MLTF) or 3 μM perifosine 
(PRIF) for 2 h in defined medium. Lipid raft isolation was performed by using Optiprep gradients. 
(b) Percentages of Pma1p associated with fraction #2 (containing detergent-resistant membranes) 
were determined by densitometry using ImageJ. (c) Fluorescence microscopy of a yeast strain 
expressing Pma1-GFP untreated (Control) or treated with the indicated ATLs as above. Data shown 
are representative of three independent experiments performed. 
 
Figure 9. Edelfosine resistance of vps29Δ and vps35Δ mutants. Growth curves of wild-type 
(BY4741), vps29Δ (vps29), vps35Δ (vps35) knock-out mutants and mutant strains harbouring the 
corresponding cognate genes (vps29-YCplac111-VPS29 and vps35-YCplac111-VPS35) in SC 
medium containing 60 µM edelfosine. Data shown are mean values ± SD of at least six independent 
experiments. 
 
Figure 10. Pma1p and edelfosine localization in wild-type S. cerevisiae and retromer mutants 
following drug addition. (a) Edelfosine-resistant retromer mutants vps29Δ and vps35Δ show the 
same pattern of ER localization as wild-type cells (WT) after treatment with PTE-ET.  (b) Retromer 
mutants vps17Δ, vps29Δ and vps35Δ show decreased vacuolar accumulation of Pma1p-GFP relative 
to wild-type cells (WT) after edelfosine (EDLF) treatment, as shown by the vacuole-accumulating 
stain FM4-64. DIC, differential interference contrast. Data shown are representative of three 
independent experiments. 
 
Figure 11. Proposed model for the mechanism of edelfosine cytotoxicity. (a) The essential proton 
pump Pma1p is associated with plasma membrane lipid rafts. (b) Edelfosine treatment causes the 
lipid raft to become disorganized. Edelfosine interacts with its core component ergosterol and Pma1p 
dissociates from the raft microdomains. (c) Edelfosine induces internalization and vacuole-
dependent degradation of Pma1p. Deletion of ESCRT-complex genes causes resistance to 
edelfosine. Pma1p could thus be degraded by ubiquitination (1), internalization by endocytosis (2), 
recognition of ubiquitin moiety by the ESCRT complex (3), leading to recycling of the ubiquitin and 
enclosement of Pma1p in lumenal vesicles of the MVB (4). Fusion of the MVB with the vacuole 
would lead to degradation of these Pma1p-containing vesicles (5). Vacuolar hydrolases could also 
degrade Pma1p. The retromer complex is essential for the effect of the drug. We postulate this 
complex is either withdrawing Pma1p from the endosome to the Golgi apparatus (GA) via retrograde 
transport (6), or allowing the delivery of lysosomal hydrolases essential for the degradation of 
Pma1p (not shown). If any of these degradation pathways are impaired, a greater quantity of Pma1p 
could be available for recycling to the plasma membrane (7). (d) Both ergosterol and edelfosine are 
internalized. The drug accumulates in the endoplasmic reticulum (ER), and in some hitherto 
uncharacterized compartment in the cytoplasm. (e) pH homeostasis in physiological conditions is 
tightly controlled by Pma1p-mediated proton extrusion, V-ATPase proton sequestering, and 
mitochondria-mediated proton pumping. Edelfosine decreases the availability of the first buffering 
mechanism, causing acidification. When edelfosine is added to cells lacking a functional V-ATPase, 
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the loss of functional Pma1p leads to a greater cytosolic acidification resulting in hypersensitivity to 
the drug. 
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Table 1. Yeast strains and plasmids used in this study. 
 
Strain Genotype Reference 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Euroscarf 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Euroscarf 
BY4743 MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 LYS2/lys2Δ0 
met15Δ0/MET15 ura3Δ0/ura3Δ0 
Euroscarf 
S288C MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0  ATCC 201389 
ERG6-RFP ERG6::RFP kanMX4 derivative of S288C P. Arvidson (25) 
PEX3-RFP PEX3::RFP kanMX4 derivative of S288C P. Arvidson (25) 
ANP1-RFP ANP1::RFP kanMX4 derivative of S288C P. Arvidson (25) 
SPC42-RFP SPC42::RFP kanMX4 derivative of S288C P. Arvidson (25) 
SNF7-RFP SNF7::RFP kanMX4  derivative of S288C P. Arvidson (25) 
SAC6-RFP SAC6::RFP kanMX4 derivative of S288C P. Arvidson (25) 
CHC1-RFP CHC1::RFP kanMX4 derivative of S288C P. Arvidson (25) 
RH1800 MATa leu2 his4 ura3-52 bar1 H. Riezman (17) 
RH2763 MATa his4 leu2 ura3 bar1 pep4::URA3 sla2-1 (end4ts) H. Riezman (17) 
 18 
Table 2. Relevant genes involved in edelfosine-induced yeast toxicity. Resistant mutants were 
identified from chemical-genomic screens of the S. cerevisiae deletion mutant collection. 
 
Functional categories associated with edelfosine-resistance analyzed in this study 
Drug 
uptake 
Vesicular traffic 
Endocytosis ESCRT complexes Retrograde transport 
 
DRS2 
DNF2 
LEM3 
AGP2 
DOC1 
 
END3 
MYO5 
RHO4 
LDB17 
Complex 0 
VPS27 
 
Complex I 
VPS23/STP22 
VPS37/SRN2 
 
Complex III 
DID4/VPS2 
VPS24 
VPS20 
Complex III related 
DID2 
VPS4 
 
Associated 
components 
BRO1 
DOA4 
UBP2 
Retromer 
VPS17 
VPS26/PEP8 
VPS29 
VPS35 
 
CORVET 
VPS3 
VPS8 
GARP complex 
VPS52 
VPS54 
 
Others 
GYP6 
SNX4 
SNX42 
CCZ1 
YPT7 
TLG2 
SWF1 
KEX1 
KEX2 
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